CVRx Q2 revenue $15.7M (+16% YoY); lowers FY2026 revenue guidance to $58-60M

CVRx, Inc.

Net loss $14.0M ($0.53/share) vs $14.7M ($0.57) in Q2 2025; cash $64.6M.
U.S. revenue $14.8M (+21% YoY) on 466 units; active implanting centers grew to 258.
Humana issued Medicare Advantage coverage policy for Barostim, effective May 1, 2026.
FY2026 guidance: total revenue $58-60M, gross margin 86-87%, operating expenses $99-101M.
Q3 2026 revenue expected between $13.5M and $14.5M; cites sales territory and payer headwinds.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.